Evidence map›Paper›PMID 39068445›Full record

ArticleWorld journal of surgical oncology2024

Nomograms to predict tumor regression grade (TRG) and ypTNM staging in patients with locally advanced esophageal cancer receiving neoadjuvant therapy.

Jianhao Qiu, Zhan Zhang, Junjie Liu, Yue Zhao, Yongmeng Li, Zhanpeng Tang, Lin Li, Yu Tian, Hui Tian

Abstract read
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jianhao Qiu *Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Zhan Zhang *Department of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Junjie LiuDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yue ZhaoDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yongmeng LiDepartment of Thoracic Surgery, Qianfoshan Hospital in the Shandong Province, Jinan, Shandong, China.
Zhanpeng TangDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Lin LiDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yu TianDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China. tianyu930314@126.com.
Hui TianDepartment of Thoracic Surgery, Qilu Hospital of Shandong University, Jinan, Shandong, China. tianhuiql@email.sdu.edu.cn.

Funding

Key Technology Research and Development Program of Shandong Province 2020CXGC011303Shandong University Clinical Research Program 2020SDUCRCA013
6 · The paper itself

Abstract

backgroundNeoadjuvant therapy (NT) has increased survival rates for patients with locally advanced esophageal cancer (EC), but estimating the impact of NT treatment prior to surgery is still very difficult.

methodsA retrospective study of the clinical information of 150 patients with locally advanced EC who got NT at Qilu Hospital of Shandong University between June 2018 and June 2023. Patients were randomized into training and internal validation groups at a 3:1 ratio. Furthermore, an external validation cohort comprised 38 patients who underwent neoadjuvant therapy at Qianfoshan Hospital in the Shandong Province between June 2021 and June 2023. Independent risk factors were identified using univariate and multivariate logistic regression (forward stepwise regression). Predictive models and dynamic web nomograms were developed by integrating these risk factors.

resultsA total of 188 patients with locally advanced EC were enrolled, of whom 118 achieved stage I of neoadjuvant pathologic TNM (ypTNM) after receiving NT and 129 achieved grades 0-1 in the tumor regression grade (TRG). Logistic regression analysis identified five independent predictors of TRG grades 0-1: pulmonary function tests (PFT), prognostic nutritional index (PNI), triglyceride (TG) levels, squamous cell carcinoma antigen (SCC-Ag) levels, and combination immunotherapy. The areas under the receiver operating characteristic (ROC) curves for the training, internal validation, and external validation groups were 0.87, 0.75, and 0.80, respectively. Meanwhile, two independent predictors of stage I of ypTNM were identified: prealbumin (PA) and SCC antigen. The areas under the ROC curves for the training, internal validation, and external validation groups were 0.78, 0.67, and 0.70, respectively. The Hosmer-Lemeshow test for both predictive models showed excellent calibration, with well-fitted calibration curves. Decision curve analysis (DCA) and clinical impact curves (CIC) have demonstrated that nomograms are of clinical utility.

conclusionThe nomograms performed well in predicting the likelihood of stage I of ypTNM and TRG grade 0-1 after NT in patients with locally advanced EC. It helps thoracic surgeons to predict the sensitivity of patients to NT before surgery, which enables precise treatment of patients with locally advanced EC.

Indexed as

Esophageal NeoplasmsNeoadjuvant TherapyNeoplasm StagingNomogramsAgedEsophagectomyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingPrognosisRetrospective StudiesEsophageal cancerImmunotherapyNeoadjuvant pathologic TNMNeoadjuvant therapyNomogramTumor regression grade

Identifiers

PMID39068445
PMCPMC11282666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.